Total Payments
$166,306
2024 Payments
$18,101
Companies
9
Transactions
157
Medicare Patients
298
Medicare Billing
$23,864
Payment Breakdown by Category
Consulting$99,404 (59.8%)
Other$42,596 (25.6%)
Travel$14,153 (8.5%)
Research$6,502 (3.9%)
Food & Beverage$3,652 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $99,404 | 28 | 59.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,596 | 18 | 25.6% |
| Travel and Lodging | $14,153 | 48 | 8.5% |
| Unspecified | $6,502 | 5 | 3.9% |
| Food and Beverage | $3,652 | 58 | 2.2% |
Payments by Type
General
$159,804
152 transactions
Research
$6,502
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $45,526 | 49 | $0 (2023) |
| GENZYME CORPORATION | $30,570 | 19 | $0 (2024) |
| GlaxoSmithKline, LLC. | $30,265 | 21 | $0 (2021) |
| Genentech USA, Inc. | $29,307 | 33 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $22,534 | 24 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $6,987 | 5 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $1,024 | 4 | $0 (2021) |
| Cook Medical LLC | $73.03 | 1 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $19.13 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,101 | 9 | GENZYME CORPORATION ($18,101) |
| 2023 | $15,391 | 14 | GENZYME CORPORATION ($9,969) |
| 2022 | $8,437 | 4 | Regeneron Pharmaceuticals, Inc. ($4,317) |
| 2021 | $12,512 | 3 | GlaxoSmithKline, LLC. ($12,350) |
| 2020 | $13,073 | 9 | GlaxoSmithKline, LLC. ($7,842) |
| 2019 | $42,217 | 52 | Genentech USA, Inc. ($15,355) |
| 2018 | $37,027 | 41 | AstraZeneca Pharmaceuticals LP ($22,689) |
| 2017 | $19,547 | 25 | GlaxoSmithKline, LLC. ($9,387) |
All Payment Transactions
157 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,436.00 | General |
| 10/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $55.13 | General |
| Category: Immunology | ||||||
| 08/29/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $39.23 | General |
| Category: Immunology | ||||||
| 08/27/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $39.23 | General |
| Category: Immunology | ||||||
| 08/22/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $11,325.00 | General |
| 08/22/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $531.44 | General |
| 08/22/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $292.67 | General |
| 08/22/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $284.28 | General |
| 08/22/2024 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $98.25 | General |
| 10/25/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $8,827.00 | General |
| Category: Immunology | ||||||
| 10/25/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $592.33 | General |
| Category: Immunology | ||||||
| 10/25/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $292.67 | General |
| Category: Immunology | ||||||
| 10/25/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $65.88 | General |
| Category: Immunology | ||||||
| 10/25/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $56.00 | General |
| Category: Immunology | ||||||
| 10/25/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: Immunology | ||||||
| 10/25/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $43.95 | General |
| Category: Immunology | ||||||
| 10/25/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | Cash or cash equivalent | $41.04 | General |
| Category: Immunology | ||||||
| 06/26/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Consulting Fee | Cash or cash equivalent | $2,148.00 | General |
| Category: Respiratory | ||||||
| 05/21/2023 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $134.41 | General |
| Category: Respiratory | ||||||
| 05/21/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $20.00 | General |
| 02/06/2023 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,080.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/06/2023 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $520.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/06/2023 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $520.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/08/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $1,250.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma • Category: Immunology | ||||||
| 09/23/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $4,317.00 | Research |
| Study: HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) | Regeneron Pharmaceuticals, Inc. | $4,317 | 1 |
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma | GENZYME CORPORATION | $1,250 | 1 |
| A randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of duplilumab in patients with severe steroid dependent asthma | SANOFI-AVENTIS U.S. LLC | $757.45 | 2 |
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma | SANOFI-AVENTIS U.S. LLC | $177.55 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 47 | 59 | $25,485 | $5,470 |
| 2022 | 5 | 82 | 115 | $29,320 | $5,913 |
| 2021 | 3 | 79 | 89 | $29,665 | $6,538 |
| 2020 | 5 | 90 | 116 | $32,695 | $5,943 |
Total Patients
298
Total Services
379
Medicare Billing
$23,864
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 28 | $13,860 | $3,163 | 22.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 31 | $11,625 | $2,307 | 19.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 40 | $15,000 | $3,239 | 21.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 22 | $5,610 | $949.49 | 16.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 15 | 26 | $3,640 | $847.27 | 23.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 13 | $3,250 | $780.13 | 24.0% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 14 | 14 | $1,820 | $97.16 | 5.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 24 | 29 | $10,875 | $2,398 | 22.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 18 | $6,750 | $1,489 | 22.1% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 14 | 14 | $4,900 | $1,203 | 24.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 13 | 15 | $3,825 | $869.25 | 22.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 13 | 13 | $3,315 | $579.50 | 17.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 30 | 48 | $18,000 | $2,819 | 15.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 12 | 15 | $3,665 | $1,027 | 28.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 23 | 25 | $6,375 | $984.42 | 15.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 14 | 15 | $2,835 | $669.15 | 23.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 11 | 13 | $1,820 | $442.15 | 24.3% |
About Dr. Lauren Cohn, MD
Dr. Lauren Cohn, MD is a Pulmonary Disease healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1306821251.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lauren Cohn, MD has received a total of $166,306 in payments from pharmaceutical and medical device companies, with $18,101 received in 2024. These payments were reported across 157 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($99,404).
As a Medicare-enrolled provider, Cohn has provided services to 298 Medicare beneficiaries, totaling 379 services with total Medicare billing of $23,864. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location New Haven, CT
- Active Since 12/14/2005
- Last Updated 06/25/2008
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1306821251
Products in Payments
- FASENRA (Drug) $28,842
- DUPIXENT (Biological) $24,229
- Xolair (Biological) $8,913
- NUCALA (Biological) $8,098
- DUPIXENT DUPILUMAB INJECTION (Biological) $6,364
- AIRSUPRA (Drug) $2,282
- TRELEGY ELLIPTA (Drug) $1,950
- COOK (Device) $73.03
- Utibron (Drug) $19.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in New Haven
Michael Imevbore, M.d, M.D
Pulmonary Disease — Payments: $271,586
Pulmonary Disease $271,586
Naftali Kaminski, Md, MD
Pulmonary Disease — Payments: $195,450
Pulmonary Disease $195,450
Wassim Fares, Md, Msc, MD, MSC
Pulmonary Disease — Payments: $128,283
Pulmonary Disease $128,283
Carrie Redlich, Md, MD
Pulmonary Disease — Payments: $8,441
Pulmonary Disease $8,441
Dr. Sushil Gupta, M.d, M.D
Pulmonary Disease — Payments: $5,175
Pulmonary Disease $5,175
Dr. Kaiser Toosy, Md, MD
Pulmonary Disease — Payments: $3,778
Pulmonary Disease $3,778